Literature DB >> 16161057

Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a Phase II clinical trial.

Ozden Altundag, Kadri Altundag, Cem Boruban, Yavuz S Silay, Selahattin Turen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16161057     DOI： 10.1002/cncr.21407

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  4 in total

1.  Respiratory Homeostasis and Exploitation of the Immune System for Lung Cancer Vaccines.

Authors:  Adam Yagui-Beltrán; Lisa M Coussens; David M Jablons
Journal:  US Oncol       Date:  2009

Review 2.  The role of cancer stem cells in neoplasia of the lung: past, present and future.

Authors:  Adam Yagui-Beltrán; Biao He; David M Jablons
Journal:  Clin Transl Oncol       Date:  2008-11       Impact factor: 3.405

3.  Construction of Prognostic Risk Model for Small Cell Lung Cancer Based on Immune-Related Genes.

Authors:  Feng Deng; Feng Tao; Zhili Xu; Jun Zhou; Xiaowei Gong; Ruhu Zhang
Journal:  Comput Math Methods Med       Date:  2022-09-30       Impact factor: 2.809

4.  Therapeutic efficacy of c-kit-targeted radioimmunotherapy using 90Y-labeled anti-c-kit antibodies in a mouse model of small cell lung cancer.

Authors:  Chisato Yoshida; Atsushi B Tsuji; Hitomi Sudo; Aya Sugyo; Tatsuya Kikuchi; Mitsuru Koizumi; Yasushi Arano; Tsuneo Saga
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.